Current Report Filing (8-k)
July 29 2019 - 6:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
July 23, 2019
ORAMED
PHARMACEUTICALS INC.
|
(Exact
name of registrant as specified in its charter)
|
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
142
W. 57
th
Street, New York, New York
|
|
10018
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
844-967-2633
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.012
|
|
ORMP
|
|
The Nasdaq Capital Market, Tel Aviv Stock Exchange
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On
July 23, 2019, Oramed Pharmaceuticals Inc. terminated the employment agreement with Mr. Mark Hasleton, effective as of August
27, 2019.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
Name:
|
Nadav
Kidron
|
|
Title:
|
President
and CEO
|
July
23, 2019
2
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Sep 2023 to Sep 2024